American Society of Hematology (ASH) Annual Meeting

December 8, 2019

PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy

Read more

Connective Tissue Oncology Society (CTOS) Annual Meeting

November 14, 2019

Clinical Response to Avapritinib by RECIST and Choi Criteria in ≥ 4th Line and PDGFRA Exon 18 Gastrointestinal Stromal Tumors (GIST)

Read more

Connective Tissue Oncology Society (CTOS) Annual Meeting

November 14, 2019

Avapritinib for the Treatment of GIST: Analysis of Efficacy, Safety, and Patient Management Strategies at the Recommended Phase 2 Dose

Read more

ISPOR Europe

November 7, 2019

Psychometric Evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF) in patients with Advanced Systemic Mastocytosis

Read more

ISPOR Europe

November 7, 2019

Psychometric Performance of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF)

Read more

Cancer Discovery

October 1, 2019

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma

Read more

Cancer Discovery

October 1, 2019

Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma

Read more

European Society for Medical Oncology (ESMO) Annual Meeting

September 30, 2019

Treatment With Pralsetinib (BLU-667), a Potent and Selective RET Inhibitor, Provides Rapid Clearance of ctDNA in Patients With RET-Altered Non-Small Cell Lung Cancer (NSCLC) and…

Read more

ASBMR 2019 Annual Meeting

September 22, 2019

A clinical update on BLU-782, an investigational selective ALK2 inhibitor in development for fibrodysplasia ossificans progressiva (FOP)

Read more

IASLC World Conference on Lung Cancer

September 9, 2019

Pralsetinib (BLU-667) demonstrates robust activity in RET-fusion-driven intracranial tumor models

Read more

European Hematology Association (EHA) Annual Meeting

June 15, 2019

Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Induces Complete and Durable Responses in Patients (pts) with Advanced Systemic Mastocytosis (AdvSM)

Read more

ASCO 2019

June 3, 2019

Clinical Activity and Tolerability of BLU-667, a Highly Potent and Selective RET Inhibitor, in Patients with Advanced RET-Fusion+ Non-small Cell Lung Cancer

Read more

ASCO 2019

June 1, 2019

Activity and Tolerability of BLU-667, a Highly Potent and Selective RET Inhibitor, in Patients with Advanced RET-altered Thyroid Cancers

Read more

ASCO 2019

June 1, 2019

Clinical Activity of Avapritinib in ≥4th Line (4L+) and PDGFRA Exon 18 Gastrointestinal Stromal Tumors (GIST)

Read more

ASCO 2019: Advancing Cancer Treatment with Precision Therapies

May 31, 2019

At the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, a key focus will be precision therapy – targeting genetic drivers of cancer with…

Read more

Blueprint Medicines Recognizes International FOP Awareness Day

April 23, 2019

Letter from Marion Dorsch, Chief Scientific Officer Today, Blueprint Medicines stands with the patient community and recognizes International Fibrodysplasia Ossificans Progressiva (FOP) Awareness Day. In…

Read more

How Our Research Platform Helped Accelerate the Discovery of BLU-667

April 10, 2019 by Jason Brubaker

Discovering potent and selective kinase drugs is a challenging endeavor. Setting up and completing a screen of a new drug target against a compound library…

Read more

American Association for Cancer Research (AACR) Annual Meeting

March 30, 2019

Discovery of BLU-667 for RET-driven cancers

Read more

Blueprint Medicines Introduces The Lens

January 2, 2019 by Marion Dorsch, Chief Scientific Officer

Welcome to The Lens, our new thought leadership platform to share our team’s expertise in precision medicine. We are pioneers in this rapidly evolving field,…

Read more

American Society of Hematology (ASH) Annual Meeting

December 2, 2018

Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM) (oral presentation)

Read more

Connective Tissue Oncology Society (CTOS) Annual Meeting

November 15, 2018

Avapritinib is Highly Active and Well-tolerated in Patients With Advanced GIST Driven by a Diverse Variety of Oncogenic Mutations in KIT and PDGFRA (oral presentation)

Read more

European Society for Medical Oncology (ESMO) Annual Meeting

October 22, 2018

Correlation of ctDNA and Response in Patients with PDGFRα D842 GIST Treated with Avapritinib (poster presentation)

Read more

European Society for Medical Oncology (ESMO) Annual Meeting

October 22, 2018

An Open-label, Randomized, Phase 3 Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Metastatic or Unresectable Gastrointestinal Stromal Tumor (poster presentation)

Read more

American Thyroid Association (ATA) Annual Meeting

October 6, 2018

Clinical activity of BLU-667, a highly selective RET inhibitor, in advanced RET-altered thyroid cancers: updated results from the phase 1 ARROW study (oral presentation)

Read more

Clinical Cancer Research

October 1, 2018

Robust activity of avapritinib, potent and highly selective inhibitor of mutated KIT, in patient-derived xenograft models of gastrointestinal stromal tumors

Read more

American Society for Bone and Mineral Research (ASBMR) Annual Meeting

September 30, 2018

BLU-782: A highly selective ALK2 inhibitor, designed specifically to target the cause of fibrodysplasia ossificans progressiva

Read more

IASLC World Conference on Lung Cancer

September 26, 2018

Activity of osimertinib and the selective RET inhibitor BLU-667 in an EGFR-mutant patient with acquired RET rearrangement (oral presentation)

Read more

Cancer Discovery

September 26, 2018

Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET…

Read more

European Hematology Association (EHA) Annual Meeting

June 15, 2018

Avapritinib (BLU-285), a Selective KIT Inhibitor, is Associated with High Response Rate and Tolerable Safety Profile in Advanced Systemic Mastocytosis: Results of a Phase 1…

Read more

American Association for Cancer Research (AACR) Annual Meeting

April 15, 2018

Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in ARROW, a phase 1 study of advanced, RET-altered solid tumors (oral presentation)

Read more

Cancer Discovery

April 15, 2018

Precision targeted therapy with BLU-667 for RET-driven cancers

Read more

American Society of Hematology (ASH) Annual Meeting

December 10, 2017

Clinical activity in a Phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (plenary oral presentation)

Read more

Connective Tissue Oncology Society (CTOS) Annual Meeting

November 10, 2017

Clinical activity of BLU-285, a highly potent and selective KIT/PDGFRα inhibitor designed to treat gastrointestinal stromal tumor (GIST) (oral presentation)

Read more

Science Translational Medicine

November 1, 2017

A precision therapy against cancers driven by KIT/PDGFRA mutations

Read more

Molecular Targets and Cancer Therapeutics (AACR – NCI – EORTC)

October 29, 2017

BLU-667 is a Potent and Highly Selective RET Inhibitor Being Developed for RET-Driven Cancers

Read more

International Liver Cancer Association (ILCA) Annual Conference

September 17, 2017

(Clinical activity Of BLU-554, a potent, highly-selective FGFR4 inhibitor in advanced HCC with FGFR4 pathway activation (oral presentation)

Read more

European Society for Medical Oncology (ESMO) Annual Meeting

September 10, 2017

Phase 1 Safety and Clinical Activity of BLU-554 in advanced hepatocellular carcinoma (oral presentation)

Read more

World Congress on Thyroid Cancer

July 30, 2017

BLU-667 is a potent and highly selective RET inhibitor in development for RET-driven thyroid cancers

Read more

American Society of Clinical Oncology (ASCO) Annual Meeting

June 5, 2017

Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST) (oral presentation)

Read more

American Association for Cancer Research (AACR) Annual Meeting

April 2, 2017

BLU-285: A potent and highly selective inhibitor designed to target malignancies driven by KIT and PDGFRα mutations (oral presentation)

Read more

American Association for Cancer Research (AACR) Annual Meeting

April 2, 2017

BLU-285: A potent and highly selective inhibitor designed to target malignancies driven by KIT and PDGFRα mutations (oral presentation)

Read more

American Society of Hematology (ASH) Annual Meeting

December 4, 2016

Preliminary Safety and Activity in a Phase 1 study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM) (oral presentation)

Read more

EORTC – NCI – AACR Molecular Targets and Cancer Therapeutics Symposium

December 1, 2016

Preliminary safety and activity in a first-in-human Phase 1 study of BLU-285, a potent, highly selective inhibitor of KIT and PDGFRα activation loop mutants in…

Read more

Molecular Targets and Cancer Therapeutics (EORTC – NCI – AACR)

November 29, 2016

First-in-human study of BLU-554, a potent, highly selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation (poster presentation)

Read more

American Association for Cancer Research (AACR) Annual Meeting

April 18, 2016

The development of Potent and Selective RET inhibitors

Read more

Journal of Clinical Investigation

May 1, 2015

Targeting cancer with kinase inhibitors

Read more

Cancer Discovery

March 16, 2015

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

Read more

Nature Communications

September 19, 2014

Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes

Read more

Nature Communications

September 10, 2014

The landscape of kinase fusions in cancer

Read more